Peptides explained in plain language
Not medical advice
Research-only

The July 2026 FDA advisory vote, explained

An FDA panel recommended allowing six peptides in pharmacy compounding. Here is what that vote does, and does not, mean.

Key takeaways

  • In July 2026, an FDA advisory committee recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon to a list that would allow pharmacy compounding.
  • FDA's own staff had recommended against adding any of them.
  • The vote is advisory. FDA must still decide and go through rulemaking, and as of October 2026 there is no final decision.
  • None of these peptides is FDA-approved, and the vote does not make online research peptides safer.

In late July 2026, headlines said an FDA panel “backed” several popular peptides. That is true, but it is easy to read too much into it. Here is what happened, in plain language.

What the committee was asked

FDA’s Pharmacy Compounding Advisory Committee is a group of outside experts. It advises FDA on which bulk ingredients pharmacies should be allowed to use when they compound medicines for individual patients. Ingredients that qualify go on what is called the 503A bulks list.

On July 23 and 24, 2026, the committee looked at seven peptides: BPC-157, KPV, TB-500, MOTS-c, emideltide (also called DSIP), Semax and epitalon.

How the votes came out

Panel recommendation Reported vote
BPC-157 Add to list 8 to 6, 1 abstention
KPV Add to list 8 to 6, 1 abstention
TB-500 Add to list 8 to 6, 1 abstention
MOTS-c Add to list 7 to 5
Semax Add to list Narrow margin
Epitalon Add to list Narrow margin
Emideltide (DSIP) Do not add 7 to 6, 1 abstention

FDA’s own staff scientists had recommended against adding any of the seven. They pointed to a lack of evidence on safety and effectiveness. Several votes were close, which shows the experts did not agree.

Get the weekly peptide brief

What changed in the rules, what new research says, and which claims to ignore. One email a week.

What the vote does not do

Advisory votes are recommendations. They do not change the law. For any of these peptides to be legally compounded, FDA would need to accept the advice and then go through formal rulemaking. That usually means a proposed rule, a public comment period and a final rule.

As of October 2026, FDA has not made a final decision. Another committee meeting is planned before the end of February 2027.

Not approved, not cleared. Even if FDA eventually adds these peptides to the bulks list, that would not make them FDA-approved drugs. Approval requires clinical trials that show a drug is safe and effective. None of these peptides has that.

How this connects to the April 2026 change

In April 2026, FDA removed 12 peptides, including several of these, from its list of compounding substances that may pose significant safety risks. That happened because the nominations were withdrawn, not because FDA found them safe. Removal alone did not make them eligible for compounding. The July vote was a separate step in a longer process.

What it means for you

  • Right now, these peptides have not been added to the 503A bulks list.
  • If someone says the vote made a peptide “FDA-approved” or “legal,” that is not accurate.
  • Products sold online “for research use only” are a different category. They are not made to medicine standards, and the vote does nothing to change their quality or safety.
  • BPC-157 and many related peptides remain banned in sport.

The bottom line

The July vote was a meaningful step, but it was advice, not a final decision. If you are curious about any of these peptides, talk with a clinician or pharmacist about what is known and what is not.

This article is for general education and isn’t medical or legal advice. It was written with AI assistance and may contain errors, so check anything that matters against the sources above and with a qualified healthcare professional before starting, stopping or changing any treatment. Why we say this.

Chris Janowski
About the author

Chris Janowski, owner and editor in chief

Chris Janowski is the editor in chief of Peptide Consumer Center. He started the site to give people a plain-language, well-sourced place to learn what peptides are, how they’re regulated and what the evidence actually says. Articles are written with AI assistance and published under his name.

Peptide Consumer Center is owned by Chris Janowski, who also owns PureVitaX, an online store that sells peptides, including several covered on this site. We link to PureVitaX, and Chris benefits when you buy there. Disclosures.